Long non-coding RNA DUXAP8 promotes the cell proliferation, migration, and invasion of papillary thyroid carcinoma via miR-223-3p mediated regulation of CXCR4

References

• Carling T, Udelsman R. Thyroid cancer. Annu Rev Med. 2014;65:125–137.
   PubMed Web of Science ®Google Scholar
• Ze Y, Zhang X, Shao F, et al. Active surveillance of low-risk papillary thyroid carcinoma: a promising strategy requiring additional evidence. J Cancer Res Clin Oncol. 2019;145:2751–2759.
   PubMed Web of Science ®Google Scholar
• Ancker OV, Krüger M, Wehland M, et al. Multikinase inhibitor treatment in thyroid cancer. Int J Mol Sci. 2019;21. DOI:10.3390/ijms21010010
   PubMed Web of Science ®Google Scholar
• Liang J, Cai W, Feng D, et al. Genetic landscape of papillary thyroid carcinoma in the Chinese population. J Pathol. 2018;244:215–226.
   PubMed Web of Science ®Google Scholar
• Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13:184–199.
   PubMed Web of Science ®Google Scholar
• Teng H, Mao F, Liang J, et al. Transcriptomic signature associated with carcinogenesis and aggressiveness of papillary thyroid carcinoma. Theranostics. 2018;8:4345–4358.
   PubMed Web of Science ®Google Scholar
• Janjua N, Wreesmann VB. Aggressive differentiated thyroid cancer. Eur J Surg Oncol. 2018;44:367–377.
   PubMed Web of Science ®Google Scholar
• Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136:629–641.
   PubMed Web of Science ®Google Scholar
• Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011;146:353–358.
   PubMed Web of Science ®Google Scholar
• Zhang H, Yu Y, Zhang K, et al. Targeted inhibition of long non-coding RNA H19 blocks anaplastic thyroid carcinoma growth and metastasis. Bioengineered. 2019;10:306–315.
   PubMed Web of Science ®Google Scholar
• Ding J, Cao J, Chen Z, et al. The role of long intergenic noncoding RNA 00511 in malignant tumors: a meta-analysis, database validation and review. Bioengineered. 2020;11:812–823.
   PubMed Web of Science ®Google Scholar
• Huang T, Wang X, Yang X, et al. Long non-coding RNA DUXAP8 enhances renal cell carcinoma progression via downregulating miR-126. Med Sci Monit. 2018;24:7340–7347.
   PubMed Web of Science ®Google Scholar
• Xu LJ, Yu XJ, Wei B, et al. Long non-coding RNA DUXAP8 regulates proliferation and invasion of esophageal squamous cell cancer. Eur Rev Med Pharmacol Sci. 2018;22:2646–2652.
   PubMed Web of Science ®Google Scholar
• Tian Y, Ma X, Yang C, et al. The impact of oxidative stress on the bone system in response to the space special environment. Int J Mol Sci. 2017;18:2132.
   Web of Science ®Google Scholar
• Sun M, Nie FQ, Zang C, et al. The pseudogene DUXAP8 promotes non-small-cell lung cancer cell proliferation and invasion by epigenetically silencing EGR1 and RHOB. Mol Ther. 2017;25:739–751.
   PubMed Web of Science ®Google Scholar
• Ma HW, Xie M, Sun M, et al. The pseudogene derived long noncoding RNA DUXAP8 promotes gastric cancer cell proliferation and migration via epigenetically silencing PLEKHO1 expression. Oncotarget. 2017;8:52211–52224.
   PubMedGoogle Scholar
• Liu Y, Zhang G, Chen H, et al. Silencing lncRNA DUXAP8 inhibits lung adenocarcinoma progression by targeting miR-26b-5p. Biosci Rep. 2020 Jan 29;41(1):BSR20200884. doi:10.1042/BSR20200884. PMID: 33269379.
   Web of Science ®Google Scholar
• Yin D, Hua L, Wang J, et al. Long non-coding RNA DUXAP8 facilitates cell viability, migration, and glycolysis in non-small-cell lung cancer via regulating HK2 and LDHA by Inhibition of miR-409-3p. Onco Targets Ther. 2020;13:7111–7123.
   PubMed Web of Science ®Google Scholar
• Zhang H, Chu K, Zheng C, et al. Pseudogene DUXAP8 promotes cell proliferation and migration of hepatocellular carcinoma by sponging MiR-490-5p to induce BUB1 expression. Front Genet. 2020;11:666.
   PubMed Web of Science ®Google Scholar
• Ji Q, Xu X, Song Q, et al. miR-223-3p inhibits human osteosarcoma metastasis and progression by directly targeting CDH6. Mol Ther. 2018;26:1299–1312.
   PubMed Web of Science ®Google Scholar
• Wang X, Tong Z, Liu H. MiR-223-3p targeting epithelial cell transforming sequence 2 oncogene inhibits the activity, apoptosis, invasion and migration of MDA-MB-468 breast cancer cells. Onco Targets Ther. 2019;12:7675–7684.
   PubMed Web of Science ®Google Scholar
• Han L, Li Z, Jiang Y, et al. SNHG29 regulates miR-223-3p/CTNND1 axis to promote glioblastoma progression via Wnt/β-catenin signaling pathway. Cancer Cell Int. 2019;19:345.
   PubMed Web of Science ®Google Scholar
• Lin Y, Ma Q, Li L, et al. The CXCL12-CXCR4 axis promotes migration, invasiveness, and EMT in human papillary thyroid carcinoma B-CPAP cells via NF-κB signaling. Biochem Cell Biol. 2018;96:619–626.
   PubMed Web of Science ®Google Scholar
• Davies L, Welch HG. Increasing Incidence of Thyroid Cancer in the United States, 1973–2002. JAMA. 2006;295:2164–2167.
   PubMed Web of Science ®Google Scholar
• Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer. 2009;115:3801–3807.
   PubMed Web of Science ®Google Scholar
• Shi X, Nie F, Wang Z, et al. Pseudogene-expressed RNAs: a new frontier in cancers. Tumour Biol. 2016;37:1471–1478.
   PubMedGoogle Scholar
• Grandér D, Johnsson P. Pseudogene-expressed RNAs: emerging roles in gene regulation and disease. Curr Top Microbiol Immunol. 2016;394:111–126.
   PubMed Web of Science ®Google Scholar
• Shore AN, Herschkowitz JI, Rosen JM. Noncoding RNAs involved in mammary gland development and tumorigenesis: there’s a long way to go. J Mammary Gland Biol Neoplasia. 2012;17:43–58.
   PubMed Web of Science ®Google Scholar
• Cheetham SW, Gruhl F, Mattick JS, et al. Long noncoding RNAs and the genetics of cancer. Br J Cancer. 2013;108:2419–2425.
   PubMed Web of Science ®Google Scholar
• Liang M, Yu S, Tang S, et al. A panel of plasma exosomal miRNAs as potential biomarkers for differential diagnosis of thyroid nodules. Front Genet. 2020;11:449.
   PubMed Web of Science ®Google Scholar
• Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11:597–610.
   PubMed Web of Science ®Google Scholar
• Towler BP, Jones CI, Newbury SF. Mechanisms of regulation of mature miRNAs. Biochem Soc Trans. 2015;43:1208–1214.
   PubMed Web of Science ®Google Scholar
• Pozzobon T, Goldoni G, Viola A, et al. CXCR4 signaling in health and disease. Immunol Lett. 2016;177:6–15.
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Behnam Azad B, Nimmagadda S. The intricate role of CXCR4 in cancer. Adv Cancer Res. 2014;124:31–82.
   PubMed Web of Science ®Google Scholar
• Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006;107:1761–1767.
   PubMed Web of Science ®Google Scholar
• Martinez-Ordoñez A, Seoane S, Cabezas P, et al. Breast cancer metastasis to liver and lung is facilitated by Pit-1-CXCL12-CXCR4 axis. Oncogene. 2018;37:1430–1444.
   PubMed Web of Science ®Google Scholar
• Xiang Z, Zhou ZJ, Xia GK, et al. A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis. Oncogene. 2017;36:5122–5133.
   PubMed Web of Science ®Google Scholar
• Guo ZJ, Yang L, Qian F, et al. Transcription factor RUNX2 up-regulates chemokine receptor CXCR4 to promote invasive and metastatic potentials of human gastric cancer. Oncotarget. 2016;7:20999–21012.
   PubMedGoogle Scholar
• Jiang Q, Sun Y, Liu X. CXCR4 as a prognostic biomarker in gastrointestinal cancer: a meta-analysis. Biomarkers. 2019;24:510–516.
   PubMed Web of Science ®Google Scholar
• He X, Wei Q, Zhang X, et al. Immunohistochemical expression of CXCR4 in thyroid carcinomas and thyroid benign lesions. Pathol Res Pract. 2010;206:712–715.
   PubMed Web of Science ®Google Scholar